Cannaphytica is working on 7 sub-classes of products to be designed and distributed to the German market and in the future to the European market when regulations will allow this.

We are working also on  several products using hemisynthetic routes from medical plants and we soon will publish the results upon approval from BfARM and opioid agency in Germany.


All our products fulfill GMP standard according to pharmaceutical industry and are consistent both on flowers and API synthesized products that we are developing in our R&D work.